Akcea Therapeutics Inc. (Nasdaq: AKCA) secured an exclusive, worldwide license from Ionis Pharmaceuticals Inc. (Nasdaq: IONS) to commercialize inotersen and AKCEA-TTR-L. Shares of Akcea Therapeutics leaped $7.80 to close at $28.14 while Ionis stock dropped $1.39 to close at $52.18.
Akcea Therapeutics secures exclusive license
March 15, 2018 at 17:07 PM EDT